
Oncology NEWS International
- Oncology NEWS International Vol 11 No 7
- Volume 11
- Issue 7
Study to Measure Impact of ProstaScint Imaging in Prostate Cancer
PRINCETON, New Jersey-Cytogen Corporation’s ProstaScint (capromab pendetide) is being evaluated in a phase I/II clinical study for its utility in helping guide intensity modulated radiation therapy (IMRT) for prostate cancer.
PRINCETON, New JerseyCytogen Corporation’s ProstaScint (capromabpendetide) is being evaluated in a phase I/II clinical study for its utility inhelping guide intensity modulated radiation therapy (IMRT) for prostate cancer.
ProstaScint is a radiolabeled monoclonal antibody that targets prostate specificmembrane antigen. In the study, the specific areas of greatest tumor burdenwithin the prostate, identified by the ProstaScint image, will receive boosteddoses of radiation via IMRT.
Articles in this issue
about 24 years ago
Good Activity for Capecitabine Confirmed in European Studyabout 24 years ago
Single-Agent Capecitabine May Benefit Elderly Colorectal Cancer Patientsabout 24 years ago
Longer Survival With FOLFOX4 in Metastatic Colorectal Cancer Patientsabout 24 years ago
Capecitabine/Vinorelbine Effective in Heavily Pretreated Patients
























































